Roth Capital Starts Stemline Therapeutics (STML) at Buy

July 30, 2013 7:02 AM EDT Send to a Friend
Roth Capital initiates coverage on Stemline Therapeutics (NASDAQ: STML) with a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login